Takeda And Lundbeck Gear Up For Big Challenge: The Brintellix Launch

17:56 EDT 1 Oct 2013 | Elsevier Business Intelligence

Lundbeck/Takeda’s newly approved antidepressant Brintellix is poised to enter the crowded, genericized antidepressant market at the end of 2013. Potential advantages in labeling include flexible dosing, lack of weight gain and lower rates of sexual...

Original Article: Takeda And Lundbeck Gear Up For Big Challenge: The Brintellix Launch

NEXT ARTICLE

More From BioPortfolio on "Takeda And Lundbeck Gear Up For Big Challenge: The Brintellix Launch"

Search BioPortfolio:
Advertisement

Relevant Topics

The Top 100 Pharmaceutical Companies
Latest News Clinical Trials Research Drugs Reports Corporate
Top 100 Pharmaceutical Companies 2012 (SCRIP 100 - http://www.scrip100.com/scrip100.html) Rank (2011 in Brackets) Company SEARCH FOR COMPANY IN BIOPORTFOLIO'S BIOCORPORATE DATABASE 2012 pharma sales...

Urology
Latest News Clinical Trials Research Drugs Reports Corporate
Urology is the branch of medicine concerned with the urinary tract and diseases that affect it. Examples include urethritis, urethrostenosis and incontinence. Follow and track Urology News on BioPortfolio: Uro...

Advertisement